Recent Updates
Recently added Catalysts

Atorvastatin pediatric appropriate formulation

Phase 1

Hypercholesterolemia | Small molecule | Metabolic |Pfizer, Inc.|Last Updated: Feb 18, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment76

FDA Designations

No designations recorded

Clinical trial landscape

Atorvastatin pediatric appropriate formulation · 1 trial · 1 indication

Phase 1 1
NCT00758004Bioequivalence Study Of Pediatric Appropriate FormulationHypercholesterolemia
COMPLETED76 Analytics
PHASE1COMPLETED
Bioequivalence Study Of Pediatric Appropriate Formulation
HypercholesterolemiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Primary study endpoints will be AUClast, AUCinf (if data permit) and Cmax from plasma atorvastatin concentration data.
5 months

Secondary Endpoints

Secondary endpoints will include Tmax and t1/2 (if data permit) of atorvastatin ; AUClast, AUCinf, Cmax, Tmax, and t1/2 (if data permit) of o-hydroxyatorvastatin and p-hydroxyatorvastatin.
5 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
ReferenceOTHERCommercial 80 mg atorvastatin tablet
TestOTHERPediatric appropriate atorvastatin 40mg formulation

Interventions

NameTypeDescription
AtorvastatinDRUGA single dose of 80 mg atrovastatin tablet
Atorvastatin pediatric appropriate formulationDRUGA single dose of pediatric appropriate atorvastatin 80 mg formulation
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy male and/or female volunteers * Mass Index (BMI) of approximately 18 to 30 kg/m2 Exclusion Criteria: * Any condition possibly affecting drug absorption * A positive urine drug screening

Countries:United States
Unlock Eligibility Criteria